Viewing nowZepajinjung 10 mg (Empagliflozin)
Empagliflozin 10mg
Tablet · Prescription medication
Jeil Pharmaceutical Co., Ltd.

MFDS item code 202105444 · Approved 2021.07.19 · Insurance code 645406610
Improvement of glycemic control in adults with type 2 diabetes mellitus
This medication is an adjunct to diet and exercise to improve blood glucose control in adults with type 2 diabetes. It can be used alone or in combination with other medications, making it effective for patients whose blood glucose is not well controlled. Caution is required when used in patients with type 2 diabetes who have cardiovascular disease, and it should be taken as directed by a specialist. This medication is used to improve blood glucose levels and aid in diabetes management.
The recommended dose of this drug is 10 mg once daily for monotherapy and as add-on therapy with other blood glucose-lowering agents, including insulin. If 10 mg of this drug is well tolerated and additional glycemic control is needed, the dose may be increased to 25 mg once daily. When this drug is coadministered with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of hypoglycemia (see Precautions for Use, 3. Adverse Reactions). This drug may be administered with or without food. Swallow the tablet whole. If you miss a dose, take it as soon as you remember. Do not take a double dose in one day. No dose adjustment is necessary for patients with mild renal impairment. Treatment with this drug should not be initiated in patients with an estimated glomerular filtration rate (eGFR) < 60 ml/min/1.73m2 [or CrCl < 60 ml/min]. In patients who tolerate this drug well and whose estimated glomerular filtration rate remains below 60ml/min/1.73m2 [or CrCl < 60 ml/min], the dose should be adjusted to or maintained at 10 mg once daily. This drug should be discontinued if the estimated glomerular filtration rate decreases to < 45 ml/min/1.73m2 [or CrCl < 45 ml/min]. This drug should not be used in patients with end-stage renal disease (ESRD) or those receiving dialysis, as efficacy is not expected in these patients. No dose adjustment is necessary for patients with mild or moderate hepatic impairment. Use of this drug is not recommended in patients with severe hepatic impairment, as it has not been studied in this population. No dose adjustment is necessary based on age. In patients 75 years of age and older, renal function and the risk of volume depletion should be considered. Initiation of this drug is not recommended in patients 85 years of age and older because clinical experience is limited (see Precautions for Use, 4. General Precautions).
This medication should not be used in certain patients. Patients with allergies to the active ingredient or ingredients in this medication, patients with type 1 diabetes or diabetic ketoacidosis, patients with severely impaired kidney function or end-stage kidney disease, and patients with genetic disorders affecting lactose breakdown should not be administered this medication. Patients with slightly reduced kidney function should use this medication with caution, and treatment should be discontinued if kidney function worsens. Additionally, its use is not recommended in patients with severe heart failure. When co-administered with insulin or insulin secretagogues, there may be a risk of hypoglycemia, requiring dosage adjustments. This medication may have various side effects, the most common being hypoglycemia, which may occur more frequently when taken with insulin or sulfonylureas. Other reported side effects include genital infections, urinary tract infections, increased urination, dehydration, low blood pressure, liver function abnormalities, etc. Particularly, serious metabolic abnormalities such as ketoacidosis may occur, so if symptoms like vomiting, abdominal pain, or difficulty breathing arise, it is important to consult a doctor immediately. Elderly patients or those at risk of fluid loss should be cautious of dehydration and low blood pressure, and it is essential to regularly monitor kidney function and fluid status. This medication requires caution when driving or operating machinery due to the risk of hypoglycemia, and if pain or swelling develops in the genital or perineal area, serious infection should be suspected, and immediate treatment is required. Pregnant or nursing women are advised to avoid using this medication, and it should be discontinued if pregnancy is confirmed. It is not used in children as the safety and efficacy of this medication have not been established. No specific toxic symptoms have been reported in cases of overdose, but if symptoms appear, immediate medical attention should be sought. This medication should be kept out of the reach of children, and it is advisable to avoid transferring it to other containers.
Not everyone experiences these, and they can vary from person to person.
This medication should be stored in a tightly closed container to protect it from air and moisture. It is recommended to maintain storage temperatures between 1 to 30 degrees Celsius at room temperature.
Pale yellow, double-convex, round film-coated tablet
Bottle - 100 tablets/bottle, Bottle - 30 tablets/bottle
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Viewing nowEmpagliflozin 10mg
Tablet · Prescription medication
Jeil Pharmaceutical Co., Ltd.

Empagliflozin 10mg
Tablet · Prescription medication
Boehringer Ingelheim Korea Co., Ltd.

Empagliflozin 25mg
Tablet · Prescription medication
Boehringer Ingelheim Korea Co., Ltd.

Empagliflozin 25mg
Tablet · Prescription medication
Donggu Bio Pharmaceutical Co., Ltd.

Empagliflozin 10mg
Tablet · Prescription medication
Dong Gu Bio Pharmaceutical Co., Ltd.

Empagliflozin 25mg
Tablet · Prescription medication
Korea Prime Pharmaceuticals Co., Ltd.

Empagliflozin 10mg
Tablet · Prescription medication
Korea Prime Pharmaceutical Co., Ltd.

Empagliflozin 25mg
Tablet · Prescription medication
Kips Biopharma Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.